Gynae BT 2017

New OAR of interest

International Evaluation of Radiotherapy Technology Effectiveness in Cervical Cancer (INTERTECC): Phase II/III Trial of Intensity Modulated Radiotherapy • International multicenter Phase II/III Trial of IMRT (45-50.4 Gy) with Cisplatin CT • Stage I-IVA cervix cancer, primary treatment or post-op, inclusion 425 patients intended • Primary Endpoint: Acute G3 Hematologic + G2 GI Toxicity • Intended: Phase III randomized trial of BM sparing IMRT vs. IMRT/ 3D CRT • Central IMRT QA (MDA and Wash U.)